Scripps Research Develops Nanodisc Technology to Enhance Vaccine Design Against HIV and Ebola
Researchers at Scripps Research, in collaboration with IAVI, have developed a new platform using nanodisc technology to study viral proteins in a more natural form. This method places proteins into lipid-based particles, mimicking the virus's outer membrane, which helps preserve the proteins' natural structure and behavior. The study, published in Nature Communications, tested this platform with proteins from HIV and Ebola, which have been challenging for vaccine development due to their complex surface proteins. The new approach offers a clearer view of how antibodies interact with viruses, potentially guiding future vaccine design. 
